Sinusitis Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sinusitis — inflammation of the paranasal sinuses (maxillary, ethmoid, frontal, and sphenoid) — is one of the most prevalent medical conditions globally, affecting approximately 135 million people annually in the United States alone, accounting for significant healthcare costs, antibiotic prescriptions, and productivity losses. The term rhinosinusitis is increasingly preferred as the nasal mucosa is invariably involved concurrently. Sinusitis is classified by duration: acute (up to four weeks), subacute (four to twelve weeks), and chronic (persisting beyond twelve weeks), with each requiring different management strategies.

The pathophysiology of sinusitis involves obstruction of the ostio-meatal complex — the drainage pathway connecting the sinuses to the nasal cavity — leading to stagnant mucus, impaired mucociliary clearance, and secondary bacterial or fungal infection. Common predisposing factors include viral upper respiratory tract infections (the most common trigger for acute bacterial sinusitis), allergic rhinitis, structural nasal abnormalities (deviated septum, concha bullosa), nasal polyps, immunodeficiency, cystic fibrosis, and dental infections.

Diagnosis is primarily clinical in acute cases: cardinal symptoms include nasal congestion, purulent anterior or posterior nasal discharge, facial pressure or pain (particularly in the maxillary, forehead, or periorbital regions), and reduced or absent sense of smell (anosmia/hyposmia). CT scanning of the sinuses is the gold standard imaging for chronic rhinosinusitis (CRS) and preoperative planning, demonstrating mucosal thickening, opacification, and anatomical variants. Nasal endoscopy confirms findings and allows direct visualisation of polyp burden and discharge. Treatment follows stepwise escalation from saline irrigation, intranasal steroids, and antibiotics for acute disease to surgical sinus drainage for medically refractory CRS.

Acute bacterial sinusitis (ABS) develops as a complication of viral upper respiratory tract infections when bacterial superinfection occurs, most commonly with Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. ABS is treated with amoxicillin-clavulanate as first-line antibiotic therapy for seven to ten days in adults and ten to fourteen days in children when antibiotic treatment is indicated — criteria include symptoms persisting beyond ten days, severe symptoms from the outset, or initial improvement followed by worsening (double-sickening pattern). Most acute sinusitis cases (60–70%) resolve without antibiotics.

Chronic rhinosinusitis (CRS) is the primary indication for functional endoscopic sinus surgery (FESS) when maximal medical therapy — at least twelve weeks of intranasal corticosteroids, daily saline irrigation, antibiotic treatment for infected exacerbations, and allergy management — has failed. CRS is further subdivided into CRS without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP). CRSwNP — characterised by bilateral eosinophilic inflammatory polyps, severe anosmia, and often comorbid asthma (the Samter's triad of polyps, asthma, and aspirin sensitivity) — is increasingly treated with biologic agents (dupilumab, mepolizumab, benralizumab) that target the underlying Th2-mediated inflammation. Allergic fungal sinusitis, chronic invasive fungal sinusitis in immunocompromised patients, and silent sinus syndrome are subspecialty rhinology conditions requiring specific surgical and medical approaches.

Medical treatment of sinusitis is appropriate for all patients with symptomatic sinonasal disease. Acute sinusitis is managed with saline irrigation, analgesics, and nasal decongestants; antibiotics are reserved for confirmed bacterial cases meeting criteria. All patients with chronic rhinosinusitis should receive a minimum of twelve weeks of optimised medical therapy — daily intranasal corticosteroids (mometasone, fluticasone), twice-daily saline nasal irrigation, allergy management for atopic patients, and antibiotic treatment for infective exacerbations — before surgical referral is appropriate.

Surgical candidacy for FESS requires failure of maximal medical therapy with documented chronic mucosal disease on CT scanning performed after a three-to-six-week oral corticosteroid course (to reduce acute inflammation and reveal the chronic disease burden). Patients with nasal polyps causing severe anosmia and bilateral obstruction, or CRS complicated by orbital or intracranial extension, may be referred for earlier surgical consideration. Absolute contraindications to FESS are few: active coagulopathy (requiring perioperative management), severe cardiovascular instability, and extensive skull base erosion from malignant or aggressive fungal disease. Patients with CRS and comorbid severe asthma require careful perioperative respiratory planning as nasal polyp treatment can significantly improve lower airway control.

Medical management of CRS begins with daily intranasal corticosteroid spray (mometasone 200 mcg or fluticasone propionate 400 mcg daily) as the cornerstone of treatment — meta-analyses confirm significant polyp volume reduction and symptom improvement with regular use. High-volume saline nasal irrigation using a neti pot or squeeze bottle with isotonic saline delivers approximately 200–240 ml per nostril twice daily, mechanically removing mucus, inflammatory mediators, and biofilm. This has Level 1 evidence for improving symptom scores and is recommended before FESS as primary medical therapy.

Short courses of oral corticosteroids (prednisolone 25–50 mg daily for five to ten days) are used to rapidly reduce severe polyp burden before medical optimisation or surgery, and provide objective assessment of reversible mucosal disease. Systemic antibiotics — macrolides (azithromycin, clarithromycin) at anti-inflammatory rather than antimicrobial doses for twelve weeks — have evidence in CRSsNP without polyps for their immunomodulatory effects on mucociliary function and cytokine production. Biologic agents including dupilumab (anti-IL-4/IL-13) are licensed for severe CRSwNP, achieving significant polyp volume reduction and anosmia improvement in pivotal clinical trials when standard treatments are inadequate.

Functional endoscopic sinus surgery (FESS) uses a 0-degree or angled nasal endoscope to navigate the nasal cavity and open the natural sinus ostia (drainage pathways) under direct vision, restoring ventilation and drainage without external incisions. The extent of surgery is tailored to the CT findings: maxillary antrostomy, anterior ethmoidectomy, frontal sinusotomy, sphenoidotomy, and posterior ethmoidectomy in combination as required. Image-guided FESS using intraoperative CT-based navigation is used for revision cases, extensive disease, or surgery near critical structures (orbit, skull base, carotid artery).

Intranasal corticosteroids achieve clinically significant improvement in nasal symptom scores in 60–70% of CRS patients after three months of regular use, and reduce polyp volume by 50–60% in CRSwNP in controlled trials. High-volume saline irrigation improves sinus symptom scores and quality of life measures in multiple RCTs. FESS for medically refractory CRS achieves statistically and clinically significant improvements in disease-specific quality of life (SNOT-22 score), nasal obstruction, facial pain, and sense of smell in 80–90% of appropriately selected patients at twelve months post-surgery.

FESS significantly reduces the frequency of acute sinusitis exacerbations, antibiotic courses, systemic corticosteroid use, and emergency presentations in the twelve months following surgery compared to continued medical management. Anosmia, which profoundly affects quality of life including eating enjoyment, hazard detection, and emotional wellbeing, improves in 50–70% of patients following FESS for CRSwNP, with complete recovery in 30–40%. Asthma control frequently improves following FESS and biologic treatment of CRSwNP, supporting the unified airway model of Th2 inflammation.

Medical treatment of sinusitis is generally safe, with the main risks being intranasal corticosteroid epistaxis (nasal bleeding from directed spray technique — using correct angulation away from the septum minimises this), and risks of systemic corticosteroid use (hyperglycaemia, insomnia, mood changes, adrenal suppression with prolonged high-dose courses). Antibiotics carry risks of gastrointestinal side effects, Clostridium difficile colitis, and antibiotic resistance with repeated courses.

FESS complications range from minor to serious. Major complications occur in less than 0.5% of cases in experienced hands: orbital haematoma (an emergency requiring immediate lateral canthotomy if vision is threatened), CSF leak with risk of meningitis, and injury to the carotid artery (extremely rare, less than 0.01%). Minor complications are more common: postoperative bleeding requiring nasal packing (2–5%), epiphora (tearing) from lacrimal duct injury (0.5%), nasal adhesion (synechia) formation at previously operated sites (5–10%), and sensory disturbance. Crusting and swelling within the sinuses in the first four to six weeks requires regular microsuction debridement in the clinic. CRS can recur after FESS, particularly in CRSwNP with poorly controlled Th2 inflammation, underlying asthma, or aspirin sensitivity; ongoing medical management is essential to prevent recurrence.

After FESS, patients typically return home the same day with nasal packing (if used) removed at 24–48 hours. Daily high-volume saline nasal irrigation starting on day two is the single most important postoperative intervention to aid mucosal healing and clear blood clots and surgical debris. A short course of oral antibiotics and corticosteroids is prescribed for the first ten to fourteen days. Nasal endoscopy with microsuction debridement — removal of crusting, blood clot, and synechia formation — is performed at one and three weeks post-operatively and is critical to optimising outcomes.

Patients are reviewed at two weeks, six weeks, three months, and six months with endoscopic assessment. Intranasal corticosteroid spray should be recommenced at two weeks and maintained long-term in CRSwNP patients. Saline irrigation should continue indefinitely, reducing to once daily after four to six weeks. Strenuous exercise, nose blowing, and contact sport should be avoided for two weeks. Air travel carries a small risk of pressure-related sinus pain and is best avoided in the first two to three weeks post-FESS. Patients with biologic prescriptions for CRSwNP continue subcutaneous injections every two to four weeks as scheduled; FESS and biologics are complementary treatments in severe disease.

Medical management of sinusitis is relatively inexpensive: generic intranasal corticosteroids cost $10–$30 per month, saline irrigation kits cost $15–$30, and acute antibiotic courses cost $20–$100. Biologic agents for severe CRSwNP (dupilumab) cost $3,000–$4,000 per month in the US without insurance coverage; prior authorisation from insurers requires documentation of failed conventional treatment. FESS in the United States as a day surgical procedure typically costs $7,000–$15,000 without insurance; insurance coverage for CRS failing medical therapy is generally available. In the UK, FESS on the NHS has waiting times of 12–18 months; private FESS costs £4,000–£8,000.

International patients can access FESS at accredited ENT centres in India, Thailand, and Malaysia at 50–70% lower cost. FESS at Apollo, Fortis, or Medanta in India costs $2,000–$5,000 all-inclusive. Thailand (Bumrungrad International, Bangkok Hospital) and Malaysia (Gleneagles, Pantai) offer comparable quality at $2,500–$6,000. Bilateral nasal polyp surgery combined with FESS is a common combined procedure available at similar savings internationally.

For patients preferring alternatives to surgery, maximal medical therapy (intranasal steroids, saline irrigation, allergen avoidance, repeated short courses of oral steroids) can provide ongoing symptom control for CRS without definitively addressing the underlying structural pathology. Allergy testing and specific immunotherapy (desensitisation) for allergic rhinitis-driven CRS can reduce mucosal inflammation and improve sinusitis outcomes when allergy is a significant contributing factor.

Balloon sinuplasty — inflation of a small balloon catheter in the sinus ostium to dilate it — is a less invasive alternative to FESS for selected patients with predominantly ostial obstruction without significant polyp disease. It can be performed under local anaesthesia in the clinic or as a brief procedure under sedation, with limited tissue trauma and faster recovery. However, balloon sinuplasty is appropriate only for limited ostial disease and cannot address polyps, significant mucosal disease, or structural pathology requiring FESS. For acute sinusitis, steam inhalation and warm facial compresses provide symptomatic relief of facial pressure, and oral decongestants (pseudoephedrine, xylometazoline) provide temporary relief of nasal congestion without addressing underlying infection.